Literature DB >> 1381907

An O-linked carbohydrate neutralization epitope of HIV-1 gp 120 is expressed by HIV-1 env gene recombinant vaccinia virus.

J E Hansen1, H Clausen, S L Hu, J O Nielsen, S Olofsson.   

Abstract

Previous studies have disagreed about the presence of O-linked carbohydrate epitopes on gp 120 of HIV, although antibodies against short-chain O-linked glycans neutralize HIV infection and block syncytium formation in vitro. To settle this question, we analysed the O-linked glycans of gp 120 by chemical methods using purified HIV-1 gp 120 from cells infected with recombinant vaccinia virus solely expressing gp 160 or gp 120. Alkaline borohydride degradation of recombinant gp 120 released monosaccharides and also slightly larger structures (di/trisaccharides) by a beta-elimination, confirming the presence of simple O-linked oligosaccharides. The functional activity as neutralisation epitopes of the O-linked oligosaccharides expressed on recombinant gp 120 was preserved, since fusion between uninfected CD4+ cells and cells infected with recombinant vaccinia was blocked by monoclonal antibodies to the O-linked oligosaccharides of gp 120. Although the mechanism for HIV induction of O-linked oligosaccharide neoantigens is unknown, these results indicate that the O-linked neutralization epitopes are inherent to the glycoprotein itself, and that the unusual appearance of simple O-linked oligosaccharides on gp 120 is independent of any interaction between the host cell and retroviral genes other than env.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381907     DOI: 10.1007/bf01309680

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  26 in total

1.  O-linked glycosylation of retroviral envelope gene products.

Authors:  A Pinter; W J Honnen
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

2.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

3.  Effects of mutations in glycosylation sites and disulphide bonds on processing, CD4-binding and fusion activity of human immunodeficiency virus envelope glycoproteins.

Authors:  A Bolmstedt; A Hemming; P Flodby; P Berntsson; B Travis; J P Lin; J Ledbetter; T Tsu; H Wigzell; S L Hu
Journal:  J Gen Virol       Date:  1991-06       Impact factor: 3.891

4.  Altered glycosylation in Madin-Darby canine kidney (MDCK) cells after transformation by murine sarcoma virus.

Authors:  E A Bruyneel; H Debray; M De Mets; M M Mareel; J Montreuil
Journal:  Clin Exp Metastasis       Date:  1990 May-Jun       Impact factor: 5.150

5.  Polyclonal antibodies to mannan from yeast also recognize the carbohydrate structure of gp120 of the AIDS virus: an approach to raise neutralizing antibodies to HIV-1 infection in vitro.

Authors:  W E Müller; H C Schröder; P Reuter; A Maidhof; G Uhlenbruck; I Winkler
Journal:  AIDS       Date:  1990-02       Impact factor: 4.177

6.  Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1.

Authors:  E Fenouillet; J C Gluckman; E Bahraoui
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

7.  Blood group A cross-reacting epitope defined by monoclonal antibodies NCC-LU-35 and -81 expressed in cancer of blood group O or B individuals: its identification as Tn antigen.

Authors:  S Hirohashi; H Clausen; T Yamada; Y Shimosato; S Hakomori
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

8.  Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1.

Authors:  P S Linsley; J A Ledbetter; E Kinney-Thomas; S L Hu
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

9.  Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus.

Authors:  J Klaniecki; T Dykers; B Travis; R Schmitt; M Wain; A Watson; P Sridhar; J McClure; B Morein; J T Ulrich
Journal:  AIDS Res Hum Retroviruses       Date:  1991-10       Impact factor: 2.205

Review 10.  Inhibitors of protein glycosylation and glycoprotein processing in viral systems.

Authors:  R Datema; S Olofsson; P A Romero
Journal:  Pharmacol Ther       Date:  1987       Impact factor: 12.310

View more
  17 in total

1.  Solution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120.

Authors:  Miklos Guttman; Maria Kahn; Natalie K Garcia; Shiu-Lok Hu; Kelly K Lee
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

2.  Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.

Authors:  J P Moore; Q J Sattentau; R Wyatt; J Sodroski
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

3.  NetOglyc: prediction of mucin type O-glycosylation sites based on sequence context and surface accessibility.

Authors:  J E Hansen; O Lund; N Tolstrup; A A Gooley; K L Williams; S Brunak
Journal:  Glycoconj J       Date:  1998-02       Impact factor: 2.916

4.  Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.

Authors:  J P Moore; J Sodroski
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

5.  Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses.

Authors:  Cathrine Scheepers; Sudipa Chowdhury; W Shea Wright; Christopher T Campbell; Nigel J Garrett; Quarraisha Abdool Karim; Salim S Abdool Karim; Penny L Moore; Jeffrey C Gildersleeve; Lynn Morris
Journal:  AIDS       Date:  2017-10-23       Impact factor: 4.177

6.  Sequence diversity of V1 and V2 domains of gp120 from human immunodeficiency virus type 1: lack of correlation with viral phenotype.

Authors:  N Wang; T Zhu; D D Ho
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

7.  Location-specific, unequal contribution of the N glycans in simian immunodeficiency virus gp120 to viral infectivity and removal of multiple glycans without disturbing infectivity.

Authors:  S Ohgimoto; T Shioda; K Mori; E E Nakayama; H Hu; Y Nagai
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

8.  Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.

Authors:  Yun Li; Bradley Cleveland; Igor Klots; Bruce Travis; Barbra A Richardson; David Anderson; David Montefiori; Patricia Polacino; Shiu-Lok Hu
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

Review 9.  Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA.

Authors:  Jean-Philippe Julien; Peter S Lee; Ian A Wilson
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

10.  Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1.

Authors:  J P Moore; R L Willey; G K Lewis; J Robinson; J Sodroski
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.